



ITW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Nicholas S. Bodor et al.

Application No.: 10/551,205

Filing Date: November 14, 2006

Title: ORAL FORMULATIONS OF
CLADRIBINE

)
)
) Group Art Unit: 1614
)
) Examiner:
)
) Confirmation No.: 4092
)
)
)
)
)

SECOND
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a Second Information Disclosure Statement (IDS) and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge _____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of _____ is enclosed for the fee due.
- ☐ Charge _____ to credit card for the fee due. Form PTO-2038 is attached.
- ☒ The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date August 10, 2007

By: Mary Katherine Baumeister
Mary Katherine Baumeister
Registration No. 26254

P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
Nicholas S. Bodor et al.)	Group Art Unit: 1614
Application No.: 10/551,205)	Examiner:
Filed: November 14, 2006)	Confirmation No.: 4092
For: ORAL FORMULATIONS OF)	
CLADRIBINE)	

SECOND INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Applicants request the Examiner's consideration of the enclosed publication cited during prosecution of the corresponding Chinese application in an Official Action dated May 11, 2007. The publication is listed on the accompanying Form PTO-1449. The reference is in Chinese; therefore, the cited section (page 105, lines 25-29) is accompanied by an English translation thereof. This reference was cited as relevant only to some of the process and product-by-process claims.

This statement, Form PTO-1449 and enclosed citation and translation are believed to be filed prior to an action on the merits. In addition, the undersigned hereby states under 37 C.F.R. § 1.97(e) that each item of information contained in this information disclosure statement was first cited in any communication from a patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement. Therefore, no fee is required to obtain consideration under 37 C.F.R. §1.97(b) or (c), whichever is applicable.

It is respectfully requested that the Examiner returned an initialed copy of applicants' enclosed Form PTO-1449 with the next official communication or with the first Action on the merits.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC


Date: August 10, 2007


By: 
Mary Katherine Baumeister
Registration No. 26254

P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620

(use as many sheets as necessary)

Sheet 1 of 1

Application Number	10/551,205	
Filing Date	November 14, 2006	
First Named Inventor	Nicholas S. Bodor et al.	
Examiner Name		
Attorney Docket No.	0056192-000024	

[illegible][illegible]

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Gao, Shen, <i>New Dosage Form and New Technology of Modern Drugs</i> , first edition, January 2002, Chapter 6, Section 3 (III) Procedures, page 105, lines 25-29 (published by People's Military Medical Publisher), and English translation thereof

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.